Vaccine makers motivation...

"The market may look through GSK's pandemic sales as being a one-off," Citigroup analyst Kevin Wilson said in a note.

"However, we believe that pandemic sales will lead to potential earnings surprises through the fourth quarter of 2009 to the second quarter of 2010 when overlaid on the rest of the business, which is now set to recover from U.S. generic washouts."

Horray for pandemics! Now, where is my smoke machine for the bee hives...